Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT03786783
Title	Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
Recruitment	Active, not recruiting
Gender	both
Phase	Phase II
Variant Requirements	No
Sponsors	National Cancer Institute (NCI)
Indications	ganglioneuroblastoma neuroblastoma
Therapies	Isotretinoin Cyclophosphamide + Thiotepa Cisplatin + Dinutuximab + Etoposide + Sargramostim Cyclophosphamide + Dinutuximab + Doxorubicin + Sargramostim + Vincristine Sulfate Dexrazoxane Cyclophosphamide + Topotecan Dinutuximab + Isotretinoin + Sargramostim Carboplatin + Etoposide + Melphalan
Age Groups:	child \| adult
Covered Countries	USA \| NZL \| AUS